PureTech grabs up to $36M from Roche to re­search milk-in­spired de­liv­ery plat­form

The qui­et R&D work that PureTech Health has been putting in­to its lym­phat­ics and im­mune cell traf­fick­ing pro­grams is pay­ing off with an an­nounce­ment this morn­ing that Roche is hand­ing up to $36 mil­lion to see if PureTech’s Mam­malian-de­rived ex­o­some plat­form tech can cre­ate oral for­mu­la­tions of Roche’s an­ti­sense ther­a­pies.

That po­ten­tial fig­ure cov­ers up­front pay­ments, re­search sup­port and ear­ly pre­clin­i­cal mile­stones. And be­yond that, Roche has al­so promised more than $1 bil­lion in store for PureTech if it reach­es cer­tain de­vel­op­ment and sales mile­stones. There’s no word on how many pro­grams they are ex­pect­ing to pur­sue un­der the agree­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER